Avadel Pharmaceuticals
AVDL
AVDL was delisted on the 11th of February, 2026.
99 hedge funds and large institutions have $559M invested in Avadel Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 35 increasing their positions, 26 reducing their positions, and 16 closing their positions.
225% more call options, than puts
Call options by funds: $11M | Put options by funds: $3.37M
35% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 26
2% less funds holding
Funds holding: 101 → 99 (-2)
13% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 16
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
23.25% less ownership
Funds ownership: 84.1% → 60.85% (-23%)
35% less capital invested
Capital invested by funds: $856M → $559M (-$297M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$41.7M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
+$13.4M |
| 3 |
RI
RTW Investments
New York
|
+$4.36M |
| 4 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$3.74M |
| 5 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$3.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$12.8M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$11.1M |
| 3 |
JMPWA
JP Morgan Private Wealth Advisors
San Francisco,
California
|
-$8.24M |
| 4 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
-$4.78M |
| 5 |
CAC
Cowen and Company
New York
|
-$4.36M |
AVDL Hedge Fund Activity: Q3 2023 in Review
99 of the 6,304 institutional investors tracked by Wall St. Rank reported a position in Avadel Pharmaceuticals (AVDL) for Q3 2023, worth a combined $559M — down 35% from $856M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of AVDL and 14 opened new positions — a net loss of 2 holders — while 26 trimmed existing stakes and 35 added.
The largest buyer was Janus Henderson Group, adding an estimated $41.7M. The largest seller was Adage Capital Partners, cutting an estimated $12.8M.
- 99 institutional investors held Avadel Pharmaceuticals (AVDL) as of Q3 2023, down from 101 in Q2 2023.
- Funds reported $559M of Avadel Pharmaceuticals stock for Q3 2023, down 35% quarter-over-quarter.
- 14 funds opened new Avadel Pharmaceuticals positions in Q3 2023 and 16 closed out, a net change of -2 holders.
- The largest Avadel Pharmaceuticals buyer in Q3 2023 was Janus Henderson Group, an estimated $41.7M added.
- The largest Avadel Pharmaceuticals seller in Q3 2023 was Adage Capital Partners, an estimated $12.8M sold.
Based on aggregated 13F filings for Q3 2023.